—

Apogee Therapeutics, Inc. Common Stock (APGE) — the peer cohort

As of 2026-10-09 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Apogee Therapeutics, Inc. Common Stock ranks 7 of 7 in its cohort on the Closelooknet composite (39/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
APGE Apogee Therapeutics, Inc. Common Stock 39 97 3 — ok 0%
HALO Halozyme Therapeutics Inc 74 93 94 51 ok 5.5%
BION.SW BB Biotech AG 73 58 96 81 info 13.8%
ONC BeiGene, Ltd. 63 77 62 32 info 8%
ARGX.BR Argen-X 62 53 74 31 info 21.3%
ARGX argenx NV ADR 62 50 73 30 info 23.1%
KRYS Krystal Biotech Inc 60 63 85 19 info 13.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-09

Quick answers

Who are Apogee Therapeutics, Inc. Common Stock's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BB Biotech AG (BION.SW), BeiGene, Ltd. (ONC), Argen-X (ARGX.BR), argenx NV ADR (ARGX), Krystal Biotech Inc (KRYS).

How does APGE score against its peers?

Apogee Therapeutics, Inc. Common Stock's composite reads 39/100, ranking 7 of 7 in its cohort as of 2026-10-09; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.